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Background: Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas
of other locations. We report a study on STS-TW forming part of the French Sarcoma Group database.
Patients and methods: Three hundred and forty-three adults were included. We carried out univariate and
multivariate analysis for overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS).
Results: Tumor locations were as follows: thoracic wall, 82.5%; abdominal wall, 12.3% and pelvic wall, 5.2%. Median
tumor size was 6.0 cm. The most frequent tumor types were unclassified sarcoma (27.7%) and myogenic sarcoma
(19.2%). A total of 44.6% of cases were grade 3. In all, 21.9% of patients had a previous medical history of
radiotherapy (PHR). Median follow-up was 7.6 years. The 5-year OS, MFS and LRFS rates were 60.4%, 68.9% and
58.4%, respectively. Multivariate analysis retained PHR and grade for predicting LRFS and PHR, size and grade as
prognostic factors of MFS. Factors influencing OS were age, size, PHR, depth, grade and surgical margins. The
predictive factors of incomplete response were PHR, size and T3.
Conclusions: Our results suggest similar classical prognostic factors as compared with sarcomas of other locations.
However, a separate analysis of STS-TW revealed a significant poor prognosis subgroup of patients with PHR.
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introduction
Soft tissue sarcomas (STS) are uncommon, biologically and
histologically heterogenous neoplasms arising from
mesenchymal tissues throughout the body [1]. Soft tissue
sarcomas of the trunk wall (STS-TW) include tumors of the
chest wall and flank, spinal and paraspinal regions and tumors
of the pelvic wall. Although less common than sarcomas arising
in the extremities, sarcomas in these locations represent 20%
of all STS [2]. STS-TW are usually studied together with
primary extremity tumors or with retroperitoneal or internal
trunk tumors, but it is not clear whether tumors in such
different localizations exhibit the same clinical behavior. Higher
median survival (34 months) has been reported for extremity
sarcomas as compared with truncal (trunk wall and internal
trunk) (20 months) or retroperitoneal (21 months) lesions [3].
Singer et al. [4] demonstrated that the location (extremity, trunk
wall and internal trunk or retroperitoneal) was important for
overall survival (OS) with significantly different survival
distributions. Moreover, tumor site has also been correlated with
the advent of local recurrences [2]. Few studies have addressed
the prognosis for patients with primary STS of the chest wall [5–
7]. Published studies reported limited patient populations
(n = 49–149) and excluded abdominal wall tumors. This study
was undertaken on a large series of trunk wall sarcoma from the
French Sarcoma Group (GSF) database as part of the Conticanet
(Connective Tissue Cancer Network) database (http://
www.conticabase.org) to examine their clinical behavior.
patients and methods
patient selection
From 1 January 1980 to 31 December 2007, 3429 consecutive adult patients
with an STS were treated for their first tumoral event in 22 participating
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cancer centers and were entered in the GSF database. Among these patients,
372 (10.8%) had a histologically proven STS arising in the trunk wall.
Twenty-nine of 372 patients who had evidence of metastatic spread at the
time of diagnosis were excluded from this study. We restricted our analysis
to patients with local disease to obtain a more homogenous patient
population. Metastasis at diagnosis is clearly an adverse prognostic factor.
The following definitions were used to distinguish the varying sites of
primary trunk wall tumor. Chest wall tumors were extrapleural neoplasms
in the region bordered superiorly by the clavicles, inferiorly by the rib
margin and medially by the medial border of the scapula. Tumors of the
scapular girdle were classified with extremity tumors. Paraspinal tumors
arose on the back from the level of the C7 vertebral body superiorly to the
base of the spine, inferiorly and medially to a line parallel with the medial
scapular border. Abdominal wall tumors were extraperitoneal neoplasms
below the inferior rib margin and above the pubis. Tumors in the intra-
abdominal area and pelvis were considered as internal trunk tumors and
were excluded from the analysis. The diagnosis of STS was based on the
conclusive clinical and imaging findings, which were then confirmed by
histological analysis.
pathology review
Histological slides of all patients entered were reviewed by the pathology
subcommittee of the GSF. This subcommittee included 20 pathologists and
a monthly slide review session was carried out. For each tumor, one to eight
slides were collegially reviewed. Immunohistochemistry was used to
confirm the diagnosis of sarcoma or for tumor typing. Histological typing
was based on the World Health Organization histological typing of soft
tissue tumors [8]. Tumor grade was evaluated according to the previously
established Fe´de´ration Nationale des Centres de Lutte Contre le Cancer
system based on tumor differentiation, mitotic count and necrosis [9, 10].
data collection
Data concerning patients, clinical tumor characteristics, treatment
modalities and their results and outcome were obtained from
a retrospective review of medical records. These and histological data were
entered into a centralized computerized database (http://
www.conticabase.org). The following nine variables were analyzed for their
potential prognostic and predictive value: age at presentation, sex, previous
medical history of radiotherapy (PHR), tumor size, tumor site (thoracic
wall, abdominal wall, pelvic wall), T of the American Joint Committee on
Cancer/ International Union Against Cancer (UICC) tumor–node–
metastasis (TNM) classification (TNM Classification of Malignant Tumors,
6th edition. New York: Wiley, 2002) (T1: tumor size < 5 cm; T2: tumor size
> 5 cm without extension to bone or to neurovascular structures; T3:
tumoral extension to bone and/or to neurovascular structures), tumor
depth (superficial or deep tumors), histological type, tumor grade and
result of surgery (complete versus incomplete).
statistical analysis
OS was computed from the date of initial diagnosis to the date of death
(whatever the cause) or last follow-up. Metastasis-free survival (MFS) was
calculated from the date of initial diagnosis to the date of first metastasis or
last follow-up, and local recurrence-free survival (LRFS) was defined from
the date of initial diagnosis to the date of first local recurrence or the date of
last follow-up only for patients with a complete response (disappearance of
all signs of cancer in response to treatment). Follow-up times were
described as medians by use of the inverse Kaplan–Meier estimator [11].
Continuous variables were expressed as median (range) and categorical
variables were expressed as percentage. Survival curves were obtained by the
Kaplan–Meier method and compared with the log-rank test. The Cox
proportional hazards model was used to calculate adjusted hazard ratios
(HRs) and their 95% confidence intervals (CIs). The link between the
variables and the achievement of a response was determined by chi-square
tests. Analysis was carried out to assess the relative influence of predictive
factors for incomplete remission, using a logistic regression model in
a forward stepwise procedure (Cox 1970). All statistical tests were two sided
and the threshold for statistical significance was P = 0.05. Variables with a P
value inferior to 0.05 were tested in the multivariate analysis. Analyses were
carried out with SPSS software (version 13.0, SPSS, Inc., Chicago, IL).
results
patient and disease characteristics
Patient characteristics are presented in Table 1. The median age
was 55.5 years (range 16.1–89.2). One hundred and forty-seven
of the 343 patients (42.9%) were male and 196 (57.1%) patients
were female. Tumor locations were as follows: thoracic wall,
283 (82.5%); abdominal wall, 42 (12.3%) and pelvic wall, 18
(5.2%). Tumor size was known in 329 cases (95.9%) and with
a median of 6.0 cm. The most frequent tumor types were
unclassified (undifferentiated) sarcoma (27.7%) and myogenic
sarcoma (rhabdomyosarcoma and leiomyosarcoma) (19.2%).
Dermatofibrosarcoma protuberans and angiosarcoma
represented 11.1% and 7.9% of the tumors, respectively. Sixty-
five cases (19%) were grade 1, 118 (34.4%) were grade 2 and
153 (44.6%) were grade 3. Two hundred and forty-seven
tumors (72%) were deeply located (infiltrating or located
beneath the superficial aponeurosis). Invasion of neurovascular
structures or bone was present in 57 patients (16.6%). Regional
node involvement was present in four patients (1.2%). Seventy-
five patients (21.9%) had a PHR in the area of the primary site.
treatment characteristics
The treatment of patients with local wall trunk sarcoma is
presented in Table 2.
local treatment. Surgical procedures were simple local excision
for 95 (27.7%), wide resection for 227 (66.2%) and unknown
for 21 (6%). Limits of surgical resection were known in 314
(91.5%) cases. Two hundred and seventy-two (79.3%) patients
had a surgical resection as macroscopically complete. We
carried out an analysis through chi-square test to demonstrate
that surgical procedures and surgical resection as
macroscopically complete rate were the same for tumors of
abdominal wall, thoracic wall and pelvis. No difference was
reported for these sublocations for surgical procedure.
However, patients with thoracic wall sarcomas had less often
a surgical resection as macroscopically complete (data not
shown). A histological evaluation of surgical margins was
available in only 125 (36.4%) cases. Radiotherapy generally
included photons or electrons with a median dose of 50 Gy.
Surgery was followed by radiotherapy for 148 (43.1%) patients
and seven (2%) patients received preoperative radiotherapy to
reduce tumor bulk.
chemotherapy. All patients who received chemotherapy were
treated with an anthracyclin-containing regimen using
a median of three drugs, which were administered for a median
of six cycles. Chemotherapy was given to 123 patients (35.8%),
as adjuvant and/or neoadjuvant treatment in 102 (29.7%)
patients or as palliative treatment in 21 (6%) patients.
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outcome
Median follow-up was 7.6 years (95% CI 6.3–9).
recurrence. At the end of the follow-up, metastatic recurrence
was observed in 90 (26.2%) patients and local recurrence in 83
(24.2%) patients.
survival analysis. OS, MFS and LRFS of the 343 patients with
trunk wall STS is depicted in Figure 1A–C. The OS rates at 5
and 10 years were 60.4% and 53.7%, respectively. The LRFS
rates at 5 and 10 years were 58.4% and 55.5%, respectively. The
MFS rates at 5 and 10 years were 68.9% and 66.4%,
respectively. One hundred forty-five patients (42.3%) were
deceased at the time of analysis, with a median OS of 155.5
months. The rate of tumor mortality was 30.6%. Other causes
of death were treatment complications in 4 (1.2%), extraneous
in 25 (7.2%) and unspecified in 11 (3.2%) cases. Median MFS
and median LRFS had not been reached.
Table 2. Treatment characteristics and outcome
Overall patients
(N = 343)
Surgical procedures, n (%)
Simple local excision 95 (27.7)
Wide resection 227 (66.2)
Unknown 21 (6.1)
Surgical resections as macroscopically complete, n (%)
Yes 272 (79.3)
No 42 (12.2)
Unknown 29 (8.5)
Surgical margins, n (%)
Microscopically complete tumor resection (R0) 96 (28)
Microscopically incomplete tumor resection (R1) 26 (7.6)
Macroscopically incomplete resection (R2) 3 (0.9)
Unknown 218 (63.5)
Radiotherapy, n (%)
No radiotherapy 185 (53.9)
Preoperative radiotherapy 7 (2)
Postoperative radiotherapy 148 (43.1)
Unknown 3 (0.9)
Chemotherapy, n (%)
No chemotherapy 219 (63.8)
Preoperative chemotherapy 23 (6.7)
Postoperative chemotherapy 62 (18)
Preoperative and postoperative chemotherapy 17 (5)
Palliative chemotherapy 21 (6.1)
Unknown 1 (0.2)
Follow-up
Follow-up, years, median, 95% CI 7.6 (6.3–9)
Overall survival, months, median 155.5
Metastasis-free survival, months, median NR
Complete response 290 (84.5)
Incomplete response 53 (15.5)
Local recurrence-free survival, months, median NR
Metastatic recurrence, n (%) 90 (26.2)
Local recurrence, n (%) 83 (24.2)
Death 145 (42.3)
CI, confidence interval; NR, not reached.
Table 1. Patients’ and disease characteristics at baseline
Overall patients
(N = 343)
Age at diagnosis, years
Median (range) 55.5 (16.1–89.2)
Sex, n (%)
Male 147 (42.9)
Female 196 (57.1)
Tumor localization, n (%)
Thoracic wall
Axillary 39 (11.4)
Anterior and lateral chest wall 123 (35.9)
Posterior chest wall 107 (31.2)
Subclavicular 9 (2.6)
Supraspinous fossa 5 (1.5)
Abdominal wall
Umbilical region 1 (0.3)
Abdominal trunk 41 (12)
Pelvis
Perineal region 16 (4.7)
Sacrococcygeal region 2 (0.6)
Tumor size (cm)
£5 145 (42.3)
‡6 and £10 128 (37.3)
>10 56 (16.3)
Unknown 14 (4.1)
Histological diagnosis and subtype, n (%)
Liposarcoma 23 (6.7)
Rhabdomyosarcoma and leiomyosarcoma 66 (19.2)
Myxofibrosarcoma 21 (6.1)
MPNST 21 (6.1)
Synovial sarcoma 20 (5.8)
Dermatofibrosarcoma protuberans 38 (11.1)
Angiosarcoma 27 (7.9)
Unclassified sarcoma 95 (27.7)
Others 32 (9.3)
Tumor grade (FNCLCC), n (%)
Grade 1 65 (19)
Grade 2 118 (34.4)
Grade 3 153 (44.6)
Unknown 7 (2)
Depth, n (%)
Superficial 96 (28)
Deep 247 (72)
TNM staging, n (%)
T1 132 (38.5)
T2 146 (42.6)
T3 57 (16.6)
Unknown 8 (2.3)
Regional node involvement, n (%)
Yes 4 (1.2)
No 339 (98.8)
PHR, n (%)
No 268 (78.1)
Yes 75 (21.9)
MPNST, malignant peripheral nerve sheath tumor; PHR, previous medical
history of radiotherapy.
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prognostic factors
prognostic factors of LRFS. In univariate analysis (Table 3), PHR
(P = 2.74 · 10213) (Figure 2), grade (P = 0.009) (Figure 3) and
histological type (P = 0.012) had a significant impact on LRFS.
In multivariate analysis, PHR (HR 4.208, 95% CI 2.632–6.728,
P = 1.95·1029) and grade (grade 2: HR 2.231, 95% CI 0.978–
5.086; grade 3: HR 2.885, 95% CI 1.290–6.45; P = 0.015)
remained statistically significant (Table 4).
prognostic factors of MFS. Univariate analysis (Table 3) showed
that seven variables were statistically correlated with MFS: PHR
(P = 0.006) (Figure 4), size (P = 0.001), depth (P = 0.002),
tumoral extension to bone and/or to neurovascular structures
(P = 0.004), grade (P = 8 · 1026) (Figure 5), histological type
(P = 0.013) and results of surgery (P = 0.002). Multivariate
analysis retained PHR (HR 2.246, 95% CI 1.339–3.767,
P = 0.002), size (size between 6 and 10 cm: HR 1.412, 95% CI
0.841–2.372; >10 cm: HR 2.635, 95% CI 1.416–4.907;
P = 0.023) and grade (grade 2: HR 2.03, 95% CI 0.757–5.44;
grade 3: HR 5.027, 95% CI 1.99–12.701; P = 2.88·1025) as
prognostic factors of MFS (Table 5). Because
dermatofibrosarcoma protuberans are tumor of intermediate
malignancy (Enzinger’s classification 2008) and consequently
do not metastasize, we carried out the same analysis excluding
this histological subtype (n = 38). In multivariate analysis,
similar prognostic factors were reported. Only crude HRs were
slightly different (data not shown).
prognostic factors of OS. The factors influencing OS in univariate
analysis were age (P = 0.00025), PHR (P = 6.4 · 1028)
(Figure 6), size (P = 5.9 · 1027), depth (P = 2.4 · 1025),
tumoral extension to bone and/or to neurovascular structures
(P = 5.6 · 1025), grade (P = 2.5 · 1027) (Figure 7), histological
type (P = 7.8 · 1025) with a better outcome for the
dermatofibrosarcoma protuberans subtype and a significantly
poorer outcome for angiosarcoma and surgical resection as
macroscopically complete (P = 7.8 · 10211) (Table 3). In the
multivariate analysis, age (HR 1.663, 95% CI 1.123–2.463,
P = 0.011), PHR (HR 2.180, 95% CI 1.361–3.492, P = 0.001),
size (size between 6 and 10 cm: HR 1.412, 95% CI 1.157–6.753;
>10 cm: HR 2.098, 95% CI 1.232–3.575; P = 0.023), depth (HR
1.728, 95% CI 1.01–2.957, P = 0.046), grade (grade 2: HR 2.796,
95% CI 1.157–6.753; grade 3: HR 4.533, 95% CI 1.903–10.8;
P = 0.001) and surgical resection as macroscopically complete
remained statistically significant (HR 2.794, 95% CI 1.773–
4.403, P = 9.44 · 1026) (Table 6).
predictive factors of complete response
Univariate analysis showed that five of the nine parameters
tested were correlated with the achievement of a complete
response of the tumor with a P < 0.05 and could be selected for
multivariate analysis (Table 7). Correlation was observed for
tumor location (P = 0.04) (thoracic and pelvic wall versus
abdominal wall). In multivariate analysis, the predictive factors
of incomplete response were PHR (P = 0.001), size (P = 0.003)
and tumoral extension to bone and/or to neurovascular
structures (P = 0.021).
comparison of patients with previous history of
radiotherapy with those with no previous history of
radiotherapy
The mean age differed significantly between the two groups:
63.7 6 13.9 versus 49.2 6 18 (P = 4.2 · 1026) (Table 8).
Figure 1. (A) Probability of overall survival of the 343 patients. (B)
Probability of metastasis-free survival of the 343 patients. (C) Probability
of local recurrence-free survival of the 343 patients.
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Female gender and angiosarcoma histological subtype were
significantly more represented in the group of patients with
PHR (P = 1.9 · 10213 and P = 1027, respectively). STS
occurred more frequently in the thoracic wall and superficial
tissue in patients with PHR (P = 0.006 and P = 0.003,
respectively). Tumoral extension to bone and/or to
neurovascular structures was greater in the group of patients
with PHR (P = 0.002). Finally, patients with PHR were less
often in complete response after a first line of treatment
(P = 3.7 · 1025). Grade and size were not associated with
previous history of radiotherapy.
discussion
STS can be classified according to their location as extremities,
head and neck, trunk wall and internal trunk (retroperitoneal
space, intra-abdominal area, pelvis and intrathoracic) [2]. This
study concerned a large series of adult patients treated for their
Table 3. Univariate analysis for prognostic factors in OS, MFS and LRFS
Factors No. of
patients
5-year
OS rate
10-year
OS rate
Log
rank
5-year
MFS rate
10-year
MFS rate
Log
rank
5-year
LRFS rate
10-year
LRFS rate
Log
rank
Age (year)
£55 172 0.674 0.626 0.00025 0.713 0.700 0.466 0.728 0.694 0.114
>55 171 0.530 0.439 0.668 0.614 0.654 0.617
Sex
Male 147 0.612 0.541 0.645 0.680 0.632 0.367 0.741 0.699 0.118
Female 196 0.598 0.536 0.704 0.691 0.652 0.622
PHR
No 268 0.676 0.608 6.4 3 1028 0.733 0.707 0.006 0.773 0.732 2.74 3 10213
Yes 75 0.328 0.251 0.501 0.429 0.292 0.292
Tumor size (cm)
£5 145 0.727 0.670 5.9 3 1027 0.772 0.737 0.001 0.735 0.688 0.819
6–10 128 0.602 0.508 0.679 0.643 0.670 0.654
>10 56 0.335 0.293 0.463 0.463 0.671 0.671
Tumor depth
Superficial 96 0.785 0.715 2.4 3 1025 0.809 0.800 0.002 0.762 0.732 0.168
Deep 247 0.539 0.474 0.650 0.607 0.662 0.625
TNM classification
T1, T2 278 0.700 0.605 5.6 3 1025 0.715 0.690 0.004 0.723 0.688 0.071
T3 57 0.401 0.401 0.579 0.526 0.532 0.532
FNCLCC grade
1 65 0.910 0.834 2.5 3 1027 0.931 0.840 8 3 1026 0.868 0.827 0.009
2 118 0.609 0.544 0.708 0.708 0.650 0.632
3 153 0.481 0.416 0.578 0.550 0.637 0.592
Histological type
Liposarcoma 23 0.771 0.675 7.8 3 1025 0.777 0.777 0.013 0.756 0.756 0.012
Rhabdomyosarcoma and
leiomyosarcoma
66 0.490 0.404 0.620 0.564 0.750 0.750
Myxofibrosarcoma 21 0.761 0.609 0.699 0.699 0.603 0.603
MPNST 21 0.508 0.444 0.749 0.655 0.686 0.686
Synovial sarcoma 20 0.671 0.537 0.615 0.615 0.654 0.561
Dermatofibrosarcoma
protuberans
38 1 0.938 0.92 0.85 0.919 0.848
Angiosarcoma 27 0.221 – 0.474 – 0.295 0.295
Unclassified sarcoma 95 0.557 0.511 0.676 0.676 0.620 0.620
Others 32 0.647 0.607 0.578 0.413 0.747 0.593
Localization
Thoracic wall 283 0.573 0.517 0.07 0.680 0.642 0.298 0.673 0.648 0.573
Abdominal wall 42 0.796 0.674 0.792 0.792 0.758 0.718
Pelvic wall 18 0.660 0.566 0.690 0.690 0.808 0.673
Surgical resections as macroscopically complete
Yes 272 0.694 0.622 7.8 3 10211 0.727 0.700 0.002 0.700 0.661 0.119
No 42 0.305 0.222 0.547 0.469 0.558 0.558
Bold values represent P < 0.05.
OS, overall survival; MFS, metastasis-free survival; MPNST, malignant peripheral nerve sheath tumor; LRFS, local recurrence-free survival; PHR, previous
medical history of radiotherapy.
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first diagnosis of local STS arising in the thoracic, abdominal
and pelvic walls. STS-TW were usually analyzed together with
STS of other primary sites [10, 12]. Some authors included
visceral and retroperitoneal tumors [13], while others studied
only STS of the chest wall [5–7] without demonstrating that
this location is a determinant of prognosis. In our study,
thoracic wall was the most frequent tumor site (82.5%) while
location was not a significant predictor of poor survival. It is
likely that surgical procedures and therapeutic strategies in
most teams remain similar, regardless of the location of STS-
TW. The main aims of this study were to identify significant
prognostic variables in a large group of localized adult STS-TW
and to determine predictive factors for the achievement of
a complete response. Some earlier studies reported STS-TW as
being rare (18.7%–20.9% of locally controlled STS) [2, 12]. In
our patient cohort, 10% of the 3429 adult patients in the whole
GSF database had STS-TW with no evidence of metastatic
spread at the time of diagnosis. Twenty-nine patients (8.4%)
had metastatic disease at the time of presentation while
metastasis rate at diagnosis was 9.7% in the whole STS
population [2]. In this study, dermatofibrosarcoma
protuberans and angiosarcoma were overrepresentated as
histological subtype in STS-TW (11.1% and 7.9%, respectively).
Figure 2. Effect of previous medical history of radiotherapy (PHR) on
local recurrence-free survival. Patients with PHR had a significantly poorer
outcome compared with those without PHR (P = 2.74 · 10213).
Figure 3. The effect of tumor grade (FNCLCC system) on local
recurrence-free survival: grade 1 versus grade 2 versus grade 3 (P = 0.009).
Table 4. Multivariate local recurrence-free survival analysis
Crude
hazard ratio
95% confidence
interval
P value
PHR 4.208 2.632–6.728 1.95 · 1029
FNCLCC grade
1 0.015
2 2.231 0.978–5.086 0.056
3 2.885 1.290–6.45 0.01
PHR, previous medical history of radiotherapy.
Figure 4. Effect of previous medical history of radiotherapy (PHR) on
metastasis-free survival. Patients with PHR had a significantly poorer
outcome compared with those without PHR (P = 0.006).
Figure 5. Effect of tumor grade (FNCLCC system) on metastasis-free
survival: grade 1 versus grade 2 versus grade 3 (P = 8 · 1026).
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Guillou et al. [10] reported only 2.4% of angiosarcoma in
a population of 410 adult patients with STS and
dermatofibrosarcoma protuberans was not a representative
histological subtype in series concerning sarcoma of the
extremities [14, 15]. It is likely that the institutions that treated
dermatofibrosarcoma protuberans were different from those that
treated other histological subtypes. The median tumor size was 6
cm and 42.3% of tumors measured <5 cm. However, series of
patients with only STS of the extremities showed approximately
the same rate of tumors measuring <5 cm [15, 16].
In STS of the extremities, local recurrences occurred in 235
patients (19%) and distant recurrences occurred in 322 patients
(26%) [16]. The actuarial 5- and 10-year LRFS rates were 79%
and 74%, respectively [16]. In the current study, local
recurrence and metastases recurrence rates were approximately
the same as for localized STS of the extremities. However, STS-
TW LRFS rates at 5 and 10 years were lower (58.4% and 55.5%,
respectively), suggesting that a microscopically complete
resection and adequate local control were more difficult to
obtain in the trunk wall, even if patients with STS-TW received
radiotherapy to the same extent (43.1%) [16]. A significant
difference was observed in LRFS between localized STS-TW
and STS of the extremities (data not reported).
In this study, histological evaluation of surgical margins was
unknown in 63.5%, which underlines the difficulty in
evaluating surgical margins as a prognostic factor in
retrospective studies. Macroscopically incomplete surgery,
grade and PHR were significantly associated with the advent of
local recurrences in multivariate analysis. The relationship
between PHR and local recurrence has not been reported so far
and appears specific to trunk wall sarcoma. The reason for this
could be the higher frequency of previously irradiated trunk
cancers, mainly breast carcinomas. Radiation-induced
sarcomas may be more infiltrative and more biologically
aggressive lesions. Therefore, patients with PHR may not
receive the optimal therapeutic strategy such as a combination
of surgery and radiotherapy. Finally, angiosarcoma was
significantly more represented in this subgroup and was mainly
multifocal. For this reason, optimal local control was not
achieved.
Table 5. Multivariate metastasis-free survival analysis
Crude
hazard ratio
95%
confidence interval
P value
PHR 2.246 1.339–3.767 0.002
Tumor size (cm)
£5 0.023
6–10 1.412 0.841–2.372 0.192
>10 2.635 1.416–4.907 0.002
FNCLCC grade
1 2.88 · 1025
2 2.03 0.757–5.444 0.159
3 5.027 1.99–12.701 0.001
PHR, previous medical history of radiotherapy.
Figure 6. Effect of previous medical history of radiotherapy (PHR) on
overall survival: patients with PHR had a significantly poorer outcome
(P = 6.4 · 1028).
Figure 7. Effect of tumor grade (FNCLCC system) on overall survival:
grade 1 versus grade 2 versus grade 3 (P = 2.5 · 1027).
Table 6. Multivariate overall survival analysis
Crude
hazard ratio
95% confidence
interval
P value
Age 1.663 1.123–2.463 0.011
PHR 2.180 1.361–3.492 0.001
Tumor size (cm)
£5 0.023
6–10 1.412 0.919–2.169 0.115
>10 2.098 1.232–3.575 0.006
Depth 1.728 1.01–2.957 0.046
FNCLCC grade
1 0.001
2 2.796 1.157–6.753 0.022
3 4.533 1.903–10.8 0.001
Surgical resections as
macroscopically complete
2.794 1.773–4.403 9.44 · 1026
PHR, previous medical history of radiotherapy.
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FNCLCC histological grade is an independent predictive
factor for metastasis development in most adult STS [12].
Unsurprisingly therefore, grade was again the most important
independent prognostic factor for MFS in this series of STS-
TW. The other independent factors were size and radiation-
induced etiology.
In the study by Sastre-Garau et al. [17], multivariate analysis
showed that three parameters were correlated with complete
removal: T of the TNM classification (T3 versus T1 or T2),
tumor site (internal trunk/retroperitoneum versus all other
sites) and the presence of necrosis foci of the tumoral tissue
(presence of necrosis versus no necrosis). In our study,
multivariate analysis showed that T3 of the TNM classification
was a predictive factor for no complete response. Tumor size
>10 cm was found to be the most important predictor with
a HR of 4.819. Obtaining complete removal after surgery is
crucial for curing STS. Predictive factors for the achievement of
complete removal have been defined whatever the location
[17]. One aim of our work was to determine the clinical and
Table 7. Predictive factors of incomplete response in univariate analysis
Factors No. of
patients
Incomplete
response,
n (%)
Complete
response,
n (%)
Log rank
Age (year)
£55 ans 172 26(15.1) 146(84.9) 0.863
>55 ans 171 27(15.8) 144(84.2)
Sex
Male 147 19(12.9) 128(87.1) 0.262
Female 196 34(17.3) 162(82.7)
PHR
No 268 30(11.2) 238(88.8) 3.72 3 1025
Yes 75 23(30.7) 52(69.3)
Localization
Thoracic and
pelvic wall
301 51(16.9) 250(83.1) 0.04
Abdominal wall 42 2(4.8) 40(95.2)
Tumor size (cm)
£5 145 11 (7.6) 134(92.4) 2.13 3 1024
6–10 128 21(16.4) 107(83.6)
>10 56 17(30.4) 39(69.6)
Tumor depth
Superficial 96 6(6.2) 90(93.8) 0.003
Deep 247 47(19) 200(81)
TNM classification
T1, T2 278 32(11.5) 146(52.5) 5.36 3 1026
T3 57 20(35.1) 37(64.9)
FNCLCC grade
1 65 6(9.2) 59(90.8) 0.139
2 118 17(14.4) 101(85.6)
3 153 30(19.6) 123(80.4)
Histological type
Liposarcoma 23 1(4.3) 22(95.7) 0.053
Rhabdomyosarcoma
and leiomyosarcoma
66 11(16.7) 55(83.3)
Myxofibrosarcoma 21 2(9.5) 19(90.5)
MPNST 21 7(33.3) 14(66.7)
Synovial sarcoma 20 1(5) 19(95)
Dermatofibrosarcoma
protuberans
38 2(5.3) 36(94.7)
Angiosarcoma 27 7(25.9) 20(74.1)
Unclassified sarcoma 95 17(17.9) 78(82.1)
Others 32 5(15.6) 27(84.4)
Bold values represent P < 0.05.
MPNST, malignant peripheral nerve sheath tumor; PHR, previous medical
history of radiotherapy.
Table 8. Patients with previous medical history of radiotherapy (PHR)
compared with those with no previous history of radiotherapy
Patients
with no PHR
(n = 268)
Patients
with PHR
(n = 75)
P
Age (year, mean 6 SD) 49.2 6 18.7 63.7 6 13.9 4.2 · 1026
Sex
Male (%) 53.4 5.3 1.9 · 10213
Female (%) 46.6 94.7
Localization
Thoracic wall (%) 79.1 94.7 0.006
Abdominal wall (%) 14.9 2.7
Pelvis (%) 16 2.7
Histological type (%) NS
Liposarcoma 8.6 0
Rhabdomyosarcoma
and leiomyosarcoma
20.5 14.7
Myxofibrosarcoma 7.5 1.3
MPNST 6 6.7
Synovial sarcoma 7.1 1.3
Dermatofibrosarcoma
protuberans
14.2 0
Angiosarcoma 0.4 34.7
Unclassified 25.4 36
Others 10.4 5.3
Histological angiosarcoma subtype (%)
Angiosarcoma 0.4 34.7 1027
FNCLCC grade (%)
1 21.8 10.7 NS
2 34.5 37.3
3 43.7 52
Tumor depth (%)
Superficial 24.3 41.3 0.003
Deep 75.7 58.7
Tumor size (cm) (%)
£5 43.5 46.4 NS
6–10 39.2 37.7
>10 17.3 15.9
TNM classification (%)
T1 39.7 38.4 0.002
T2 46.9 31.5
T3 13.4 30.1
Complete response after the first line of treatment (%)
Yes 88.8 69.3 3.7 · 1025
No 11.2 30.7
Bold values represent P < 0.05.
MPNST, malignant peripheral nerve sheath tumor; SD, standard deviation;
NS, not significant.
original article Annals of Oncology
1134 | Salas et al. Volume 20 | No. 6 | June 2009
pathological parameters that can be determined before surgery
and are associated with failure to obtain a complete response at
the end of the primary multimodal treatment of STS-TW.
Predictive parameters may be taken into account in any
assessment of tumors in order to specify the indications for
conservative surgery and those for radio- or chemotherapy as
preoperative approaches to STS-TW. In this regard, PHR and
size were specific for this particular STS location.
In contrast with series of STS of the extremities or series of
sarcomas irrespective of tumor localization, a separate analysis
of STS-TW revealed a significant subgroup of patients with
PHR, representing 21.9% of cases in this site. Patients with PHR
were female (94.7%) and older (mean age: 63.7 6 13.9). The
main initial tumor treated with radiotherapy was breast cancer
and radio-induced sarcomas were mainly angiosarcomas of the
thoracic wall in which complete tumor removal was difficult to
achieve. Furthermore, PHR was associated with poorer OS and
MFS. PHR was a predictive factor of no complete response.
Therapeutic radiation for malignant and benign diseases has
been associated with secondary malignancies, including
sarcomas [18, 19]. Radiation-induced sarcoma has been
reported but mainly in single case reports and several very small
series [20] concerned the most common subtypes like
angiosarcoma, osteosarcoma, fibrosarcoma and MFH [18, 19,
21–23]. The prognosis for patients with postradiation solid
tumors, and sarcomas in particular, is poor [19, 24]. Tumors in
areas with prior irradiation may behave more aggressively and
progress more rapidly [25]. Our findings demonstrate that PHR
is a major prognostic and predictive factor in STS-TW, so
patients with PHR should be considered separately.
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